Psychosis and pathological drug dependence: Towards an integrated, multi-modal approach;Psicosi e dipendenze patologiche da sostanze: Verso un approccio integrato multi-modale

Giornale Italiano di Psicopatologia

Volumn 8, Issue 1, 2002, Pages 36-58

  Manna, Vincenzo ^a,b   Daniele, M T ^a   Pinto, M ^a  

^a Dipartimento Salute Mentale   (Italy)

^b Dipartimento Salute Mentale   (Italy)

Author keywords

Alcohol Addiction; Drug Dependence; Psychiatric Comorbidity; Psycho Pathological Continuum; Psychotic Disorders; Substances Abuse

Indexed keywords

ALCOHOL; FLUOXETINE;

ALCOHOL ABUSE; ARTICLE; COMORBIDITY; CORRELATION ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; HUMAN; PATHOPHYSIOLOGY; PSYCHODYNAMICS; PSYCHOSIS; PSYCHOTHERAPY; SELF MEDICATION; SOCIAL SUPPORT; SUBSTANCE ABUSE;

EID: 0036523211     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (188)

1. Manna V, Ruggiero S. Dipendenza patologica da sostanze: Comorbilità psichiatrica o continuum psicopatologico? Riv Psichiatr 2001;36,1:1-13.
2. Manna V, D'adduzio A. Considerazioni sul fenomeno tossicodipendenza nell'ambito della A.S.L. FG/3 negli ultimi cinque anni. Gazzetta Sanitaria della Daunia 2000;50,3:29-44.
3. Edwards G, Arif A, Hodgson R. Nomenclature and classification of drug and alcohol-related problems: A WHO memorandum. Bull World Health Org 1981;59,2:225-42.
4. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry 1990;157:25-33.
5. Pozzi G, Bacigalupi M, Serretti A, Tempesta E. Prevalenza dei disturbi mentali fra gli utenti dei servizi pubblici per le tossicodipendenze in Italia: Uno studio multicentrico. Bollettino Farmacodip Alcol 1993;16:3-4.
6. Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Arch Gen Psychiatry 1986;43:739-49.
7. Regier DA, Farmer ME, Rae BS. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. J Am Med Ass 1990;264:2511-8.
8. Kessler RC, Mcgonagle KA, Shanyang Z. Lifetime and 12-mounth prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV). Washington D.C.: Am Psychiatr Press 1994.
10. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994;165:13-21.
11. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psycology 1992;60,6:845-56.
12. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Mental Dis 1987;175,11:641-52.
13. Le Duc PA, Mittleman G. Schizophrenia and psycho-stimulant abuse: A review and reanalysis of clinical evidence. Psycopharmacology 1995;121:407-27.
14. Galanter M, Castaneda R, Ferman J. Substance abuse among general psychiatric patients: Place of presentation, diagnosis, and treatment. Am J Drug Alcohol Abuse 1988;14,2:211-35.
15. Goff DC, Henderdson DC, Amico BS. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94.
16. Glassman AH. Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 1993;150:546-53.
17. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993;88:1327-34.
18. Manna V, Di Rienzo AM, Caccianotti B, De Maio MSA. Correlati neuro-biologici delle farmaco-tossicodipendenze. Gazzetta Sanitaria della Daunia 1996;46,3:72-7.
19. Manna V, Di Rienzo Am, Caccianotti B, De Maio MSA. Neuro-biologia delle farmaco-tossicodipendenze. Neurol Psichiatr Sci Um 1997;17,3:367-79.
20. Tempesta E, Pozzi G. Sostanze d'abuso e psicosi. Med Tossicodipend 1996;IV,2-3:32-43.
21. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 1992;654:160-70.
22. Piazza PV, Deminiere JM, Le Moal M, Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989;245:1511-21.
23. Gawin FH. Cocaine addiction: Psychology and neurophysiology. Science 1991;251:241-8.
24. Miller NS, Mahler JC, Gold MS. Suicide risk associated with drug and alcohol dependence. J Addict Dis 1991;10:49-61.
25. Przybeck Tr, Helzer JE. ECA community survey. J Studies Alcohol 1988;49:219-24.
26. Lehman Af, Myers Cp, Corty E. Assessment and classification of patients with psychiatric and substance abuse syndromes. Hosp Comm Psychiatry 1989;40:1019-25.
27. Galanter M, Kleber HD. Trattamento dei Disturbi da Uso di Sostanze. Milano: Masson 1998.
28. Miller FT, Busch F, Hertz Tanenbaum J. Drug abuse in schizophrenia and bipolar disorders. Am J Drug Alcohol Abuse 1989;15:291-5.
29. Kiesler CA, Simpkins CG, Morton TL. Prevalence of dual diagnoses of mental and substance abuse disorders in general hospitals. Hosp Community Psychiatry 1987;38:511-4.
30. Siris SG, Docherty JP. Psycho-social management of substance abuse in schizophrenia. In: Hertz MI, Dockerty JP, Klein SK, eds. Handbook of Schizophrenia, Vol. 4: Psychosocial Therapies. New York: Elsevier 1990:339-54.
31. Shaner A, Khalsa ME, Roberts L. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993;150:758-62.
32. Appleby L, Luchins DJ, Dyson V. Effects of mandatory drug screens on substance use diagnoses in a mental hospital population. J Nerv Mental Dis 1995;183:183-4.
33. Sanguineti VR, Brooks MO. Factors related to emergency commitment of chronic mentally ill patients who are substance abusers. Hosp Community Psychiatry 1992;43:237-41.
34. Szuster RR, Schanbacher BL, Mc Cann SC, Mc Donnell A. Underdiagnosis of psycho-active substance induced organic mental disorders in emergency psychiatry. Am J Drug Alcohol Abuse 1990;16:319-27.
35. Woodward B, Fortgang J, Sullivan Trainor M. Underdiagnosis of alcohol dependence in psychiatric inpatients. Am J Drug Alcohol Abuse 1991;17:373-88.
36. Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Community Psychiatry 1989;40:1031-6.
37. Alfs Ds, Mclellan AT. A day hospital program for dual diagnosis patients in a VA medical center. Hosp Community Psychiatry 1992;43:241-4.
38. Mueser KT, Yarnold PR, Levinson DF. Prevalence of substance abuse in schizophrenia. Schizophr Bull 1990;16:31-55.
39. Dixon L, Haas G, Weiden PJ. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry 1991;148:224-30.
40. National Institute on Drug Abuse. National Household Survey on Drug Abuse: Population Estimates. 1985. DHHS Pub.No.(ADM) 87-1539. Rockville: The Institute; 1987.
41. Brady K, Casto S, Lydiard RB. Substance abuse in an inpatient psychiatric sample. Am J Drug Alcohol Abuse 1991;17:389-97.
42. Caton CLM, Granlick A, Bender S, Simon R. Young chronic patients and substance abuse. Hosp Community Psychiatry 1989;40:1037-40.
43. Drake RE, Wallach MA. Substance abuse among schizophrenic patients. Am J Psychiatry 1989;40:1041-67.
44. Lyons JS, Mcgovern MP. Use of mental health services by dually diagnosed patients. Hosp Community Psychiatry 1989;40:1067-9.
45. Brady K, Anton R, Ballager JC. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990;147:1164-7.
46. Tien Ay, Anthony JC. Epidemiological analysis of alcohol and drug use as factors for psychotic experiences. J Nerv Mental Dis 1992;180:595-6.
47. Cuffel BJ, Chase P. Remission and relapse of substance use disorders in schizophrenia. Result from one-year prospective study. J Nerv Mental Dis 1994;182:342-8.
48. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-9.
49. Gupta S, Hendricks S, Kenkel AM. Relapse in schizophrenia: Is there a relationship to substance abuse? Schizophr Bull 1966;20:153-6.
50. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Bull 1996;20:145-51.
51. Dixon L, Mcnary S, Lehman A. One year follow-up of secondary versus primary mental disorders. Am J Psychiatry 1997;154:1610-2.
52. Kovasznay B, Bromet E, Schwartz JE. Substance abuse and onset of psychotic illness. Hosp Community Psychiatry 1993;44:567-71.
53. Seibyl JP, Satel SL, Anthony D. Effects of cocaine on hospital course in schizophrenia. J Nerv Mental Dis 1993;181:31-7.
54. Safer DJ. Substance abuse by young adult chronic patients. Hosp Community Psychiatry 1987;38:511-4.
55. Anthony JC. Epidemiology of drug dependence. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. Second Edition. Washington: American Psychiatric Press 1999:47-58.
56. Pristach Ca, Smith CM. Medication compliance and substance abuse among schizophrenic patients. Hospital Community Psychiatry 1990;41:1345-1348.
57. Miller FT, Hertz Tenenbaum J. Drug abuse in schizophrenia. Hosp Community Psychiatry 1989;40:847-9.
58. Kodoef L. Outpatients treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986;143:867-72.
59. Kashner TM, Radr LE, Rodell DE. Family characteristics substance abuse, and hospitalization patterns of patients with schizophrenia. Hosp Community Psychiatry 1991;42:195-7.
60. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication non-compliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-8.
61. Fariello D, Scheidt S. Clinical case management of the dually diagnosed patient. Hosp Community Psychiatry 1989;40:1065-7.
62. Howland RH. Barriers to community treatment of patients with dual diagnosis. Hosp Community Psychiatry 1990;41:1134-5.
63. Ridgely MS, Lambert D, Goodman A. Interagency collaboration in services for people with co-occurring mental illness and substance use disorder. Psychiatr Serv 1998;49:236-8.
64. Clark RE. Family costs associated with severe mental illness and substance use. Hosp Community Psychiatry 1994;45:808-13.
65. Bertrando P. Misurare la Famiglia. Torino: Bollati Boringhieri 1997.
66. Horwath E. Clinical presentation of AIDS and HIV infection in state psychiatric facilities. Hospital Community Psychiatry 1989;40:502-6.
67. Baker Dg, Mossman D. Potential HIV exposture in psychiatrically hospitalized adolescent girls. Am J Psychiatry 1991;148,4:528-30.
68. Cournos F. HIV infection in state hospitals: Case reports and long-term strategies. Hosp Community Psychiatry 1990;41:163-6.
69. Cournos F. HIV seroprevalence patients admitted to two psychiatric hospitals. Am J Psychiatry 1991;148,9:1225-30.
70. Sacks M. Undetected HIV infection among acutely ill psychiatric inpatients. Am J Psychiatry 1992;149,4:544-5.
71. Treffert DA. Marijuana use in schizophrenia: A clear hazard. Am J Psychiatry 1978;135:1213-5.
72. Hall R, Stickney SK, Gardner ER. Relationship of psychiatric illness to drug abuse. J Psychoactive Drugs 1979;11:337-42.
73. Hekimian LJ, Gershon S. Characteristics of drug abusers admitted to a psychiatric hospital. JAMA 1968;295:125-130.
74. Knudsen P, Vilamr T. Cannabis and nettroleptic agents in schizophrenia. Acta Psychiatr Scand 1984;69:162-74.
75. Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North America 1986;9:533-45.
76. Dixon L, Haas G, Weiden P. Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self reports. Schizophr Bull 1990;16:69-79.
77. Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. Psychological Medicine 1974;4:255-61.
78. Tsuang MT, Simpson JC, Kronfol Z. Subtipes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch Gen Psychiatry 1982;39:141-7.
79. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985;46:79-83.
80. Weller MPI, Ang PC, Latimer-Sayer DT, Zachary A. Drug abuse and mental illness (letter). Lancet 1988;I:997.
81. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: The role of pre-morbid adjustment. Psychol Med 1992;39:141-7.
82. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and non-users of cannabis. Acta Psychiatr Scand 1989;79:505-10.
83. Halikas JA, Goodwin DW, Guze SB. Marijuana use and psychiatric illness. Arch Gen Psychiatry 1972;27:162-5.
84. Johnson BS, Smith BL, Taylor P. Cannabis and schizophrenia. Lancet 1988;I:592-3.
85. Negrete JC. Cannabis and schizophrenia. Br J Add 1989;84:349-51.
86. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry 1992;161:648-53.
87. Cuffel Bj, Heithof Ka, Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Community Psychiatry 1993;44:247-51.
88. Bickley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment resistant schizophrenia: Charactristics and implications for clozapine therapy. Am J Psychiatry 1994;151:385-9.
89. Washton A, Gold M, Pottash A. Survey of 500 callers to a National Cocaine Helpline. Psychosomatics 1984;25:771-5.
90. Weiss R, Mirin S. Subtypes of cocaine abusers. Psychiatr Clin North America 1986;9:491-501.
91. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Mental Dis 1994;182:109-12.
92. Serper Mr, Alpert M, Richardson NA. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 1995;152:1464-9.
93. Miller F, Hertz Tanenbaum J, Goodwin C, Igel J. Cocaine and polysubstance abuse by psychiatric inpatients. Hosp Community Psychiatry 1990;41:1251-3.
94. Brunette MF, Mueser KT, Xie H, Drake RE. Relationship between symptoms qf schizophrenia and substance abuse. J Nerv Mental Dis 1997;185:13-20.
95. Readon GT. Brachet creep. The changing pattern of neuroleptic dosages over a decade. Am J Psychiatry 1989;146:726-9.
96. Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16:111-22.
97. Bowers MB Jr, Swingar ME. Vulnerability to psychosis associated with allucinogen use. Psychiatry Res 1983;9:91-7.
98. Kendler KS. A twin study of individuals with both alcoholism and schizophrenia. Br J Psychiatry 1985;147:524-31.
99. Noordsy DL, Drake RE, Biesanz JC, Mchugo GJ. Family history of alcoholism in schizophrenia. J Nerv Mental Dis 1994;182:651-5.
100. Maremmani I, Canoniero S, Zolesi O. Forme cliniche del craving e farmaci anticraving. Itaca 1999;7:20-39.
101. Manna V, Agnoli A. Aspetti nosografici e biologici delle sindromi depressive: Recenti acquisizioni. G Neuro-Psico-Farmacol 1983;6:249-60.
102. Kraepelin E. Die erscheinungsformen des irreseins. Zeitshrift fur die gesante. Neurol Psychiatr 1920;62:1-29.
103. Crow TJ. The failure of the kraepelininan binary concept and the search for the psychosis gene. In: Kerr A, McClelland H, eds. Concepts of Mental Disorders. London: Royal College of Psychiatrist 1991.
104. Breier A, Charney DS, Heninger GR. The diagnostic validity of anxiety disorders and their relationship to depressive illness. Am J Psychiatry 1985;142:787-97.
105. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, (DSM III-R) Washington D.C.: American Psychiatric Press, 1987.
106. Van Praag Hm, Asnis Gm, Brown Sl, Korn M. Beyond serotonin. A multiaminergic perspective on abnormal behavior In: Brown SL, Van Praag HM, eds. The Role of Serotonin in Psychiatric Disorders. New York: Brunner-Mazel Publ 1991.
107. Van Praag HM. «Make Believes» in Psychiatry or the Perils of Progress. New York: Brunner-Mazel Publ 1993.
108. Bolino F, Di Michele V, Manna V, Di Cicco L, Casacchia M. Information-processing deficits in schizophrenic and schizo-affective disorders. J Psychophysiol 1993;7,4:348-9.
109. Manna V. La reazione di allerta nei pazienti schizofrenici. Modificazioni dei parametri neurofisiologici e loro significato funzionale. Gazzetta Sanitaria della Daunia 1994;44,1:40-8.
110. Bolino F, De Michele V, Di Cicco L, Manna V, Daneluzzo E, Casacchia M. Sensorimotor gating ad habituation evoked by electro-cutaneous stimulation in schizophrenia. Biol Psychiatry 1994;36:670-9.
111. Wexler BE. Beyond the kraepelinian dichotomy. Biol Psychiatry 1992;31:539-41.
112. Benkelfat C. Serotoninergic mechanism in psychiatric disorders: New research tools, new ideas. Int Clin Psychopharmacol 1993;(suppl 2):53-6.
113. Winokur G, Rimmer J, Reich T. Alcoholism. Is there more than one type of alcoholism? Br J Psychiatry 1971;118:525-31.
114. Rounsaville BJ, Kosten TR, Weissman MM. Psychiatric disorders in relatives of probands with opiate addictions. Arch Gen Psychiatry 1991;48:33-42.
115. Manna V. Stress, integrazione socio-ambientale e salute mentale nella valutazione multiassiale secondo il DSM-III R. Psichiatria e Territorio 1990;1:63-75.
116. Cibin M. Alcol e disturbi mentali. L'approccio multimodale alla dipendenza alcolica. Psichiatria e Territorio 1996;3:287-97.
117. Manna V, Mescia G, Ferrone Mc, Giordano MA. Ouroboros: Il serpente alchemico. Verso l'integrazione tra psicoterapia e farmacoterapia nel trattamento dei disturbi mentali correlati all'abuso di sostanze. G It Psicopatol 1998;2:209-16.
118. Mosti A, Giuseppone Ar, Montanari L, Giannotti CF. L'attività alcologica in Emilia Romagna: Un progetto nato dal basso. Boll Farmacodip Alcol 1998;1:21-31.
119. Carey BK. Emerging treatment guidelines for mentally ill chemical abusers. Hosp Community Psychiatry 1989;40:341-9.
120. Osher FC, Kofoed LL. Treatment of patients with psychatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 1989;40:1025-30.
121. Humphreys K, Moos RH, Hamilton EG. Psychiatric services in VA substance abuse treatment programs. Psychiatr Serv 1996;47:1203-8.
122. Manna V, Lattanzio M. Aspetti diagnostici delle sindromi e dei disturbi associati alle dipendenze patologiche da sostanze. Difesa Sociale, Istituto Italiano di Medicina Sociale 2000;1-2:119-34.
123. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: Alcohol, cocaine, opiods. Am J Psychiatry 1995;152(suppl.):2-59.
124. Clerici M, Albertini E, Bertrando P. Emotivita espressa familiare nei disturbi da uso di sostanze. Riv Riab Psichiatr Psicosoc 1993;2,3:137-47.
125. Hellerstein Dj, Meehan B. Outpatients group therapy for schizophrenic substance abusers. Am J Psychiatry 1987;144:1337-9.
126. Galanter M, Kleber HD. Textbook of Substance Abuse Treatment. Second Edition. Washington: Am Psychiatr Press 1999.
127. Manna V. L'assordante Silenzio della Libertà. Appunti per Una Prevenzione Scientificamente Orientata del Fenomeno Droga. Foggia: Leone Ed., 1992.
128. Wise RA, Bozart MA. Brain substrates for reinforcement and drug self-administration. Progr Neuropsychopharmacol 1981;5:467-469.
129. Gray JA. The Neuropsychology of Anxiety: An Inquiry Into the Function of the Septo-Hippocampal System. Oxford: Oxford University Press 1982.
130. W.H.O. Report. The craving for alcohol. Expert Committee on Mental Health and on Alcohol. Quarterly J Stud Alcohol 1955;16:33-66.
131. Skinner BF. Cognitive science and behaviourism. Br J Psychology 1985;76:291-301.
132. Wickler A. Recent progress in research on the neurophysiologic basis of morphine addiction. Am J Psychiatry 1948;2:105-115.
133. Kohut H. The Analysis of the Self. New York: International Universities Press 1971.
134. Kohut H. The Restoration of the Self. New York: International Universities Press 1977.
135. Kozlowski LT, Wilkinson DA. Use and misuse of the concept of craving by alcohol, tobacco and drug researchers. Br J Addiction 1987;14:443-5.
136. Maremmani I, Zolesi O, Aglietti M, Lubrano S, Placidi GF. Neurotrasmettitori implicati nella fisiopatologia del craving e farmaci anticraving. G It Psicopatol 1998;2:273-87.
137. Karasu TB. Psychotherapy and pharmacotherapy: Toward an integrativ model. Am J Psychiatry 1982;139:1102-13.
138. Klerman GL. Combining drugs and psychotherapy in the treatment of depression. In: Cole JO, Schatzberg AF, Frazier SH, eds. Depression: Biology, Psychodynamics and Treatment. New York: Plenum Press 1978:213-27.
139. Docherty JP, Marder SR, Van Kammen DP. Psychotherapy and pharmacotherapy: Conceptual issues. Am J Psychiatry 1977;134:529-33.
140. Wylie HW Jr, Wylie ML. An effect of pharmacotherapy on the psychoanalytic process: Case report of a modified analysis. Am J Psychiatry 1987;144:489-92.
141. Loeb FF, Loeb LR. Psychoanalytic observation on the effect of lithium on manic attacks. J Am Psychoan Ass 1987;35:877-902.
142. Cibin M, Giannini L, Gallimberti L. Il drop-out nel trattamento ambulatoriale dell' alcoldipendenza. Psichiatr Psicoter Anal 1984;2:368-72.
143. Narajo CA, Kadlec KE, Sanhueza P. Fluoxetine differentially alters alcohol intake and other consumatory behaviours in problem drinkers. Clin Pharmacological Ther 1990;4:490-2.
144. Gerra G, Fertonani Affini G, Caccavari R, Zaimovic A, Tagliavini P, Riva M, et al. Gamma-hydroxy-butyric acid in the treatment of heroin addicition. New Trends Clin Neuropharmacol 1994;4:357-62.
145. Cibin M, Gentile N, Ferri M, Canton G, Le Grazie C, Gallimberti L. S-Adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In: Biomedical and Social Aspects of Alcoholism. Amsterdam: Elsevier Publ. Co. 1988:357-70.
146. Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. Gamma-hydroxy-butyric acid in treatment of alcohol dependence: A double blind study. Alcohol Clin Exp Res 1992;16:673-6.
147. Gessa GL, Colombo G. L'acido-gamma-amino-butirrico (GHB): Un neurotrasmettitore, una medicina, una sostanza d'abuso. Boll Farmacodipendenze e Alcolismo 1998;1:43-6.
148. Kranzler HR, Orrok B. The pharmacotherapy of alcoholism. In: Tasman E, Hales RE, Frances AJ, eds. Review of Psychiatry. Washington D.C.: American Psychiatric Press 1989.
149. Bressa GM. S-Adenosyl-Methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 1994;89:(suppl. 154)7-14.
150. Lieber CS, Williams R. Recent advances in the treatment of liver diseases. Drugs 1990;40:(suppl.3)111-38.
151. Walker KN. Social support networks and the crisis of the bereavement. Soc Sci Med 1977;2:35-41.
152. Sartori P. L'intervento sociale nel trattamento dell'alcoldipendenza: Strategie teoriche e modelli di applicazione. In: Ferrara SD, Gallimberti L, eds. La Dipendenza Alcolica. Padova: ARFI RICERCA, Monografia 1, 1988.
153. Manna V. Il disagio giovanile come disagio della civiltà: Alla ricerca di valori umani autentici nella prospettiva della psicologia trans-personale. Gnosis 1994;9:12-24.
154. Alibrandi LA. The «folk psychotherapy» of alcoholics anonimous. In: Zimberg S, Wallace J, Blume SB, eds. Practical Approaches to Alcoholism Psychotherapy. New York: Plenum Press 1978.
155. Cibin M. Basi teoriche, organizzazione e funzione dei gruppi di auto-aiuto. In: Ferrara SD, Gallimberti L, eds. La Dipendenza Alcolica. Padova: ARFI RICERCA, Monografia 1, 1988.
156. Bergeret J. Depressione e Stati Limite. Roma: II Pensiero Scientifico Ed. 1976.
157. Khantzian EJ, Mack JE. Alcoholics anonimous and contemporary psychodynamic theory. In: Galanter M, ed. Recent Development in Alcoholism Vol. 7. New York: Plenum Press 1989.
158. Blatt SJ, Mc Donald C, Sugarman A. Psychodynamic theories of opiate addiction: New direction for research. Clinical Psychology Review 1984;4:159-189.
159. Vaillant GE. The alcohol-dependent and drug-dependent person. In: Nicholi AM Jr. Ed. The New Harvard Guide to Psychiatry. Cambridge M.A.: Belknap Press of Harvard University Press 1988.
160. Khantzian EJ. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-64.
161. Khantzian EJ. A contemporary psychodynamic approach to drug abuse treatment. Am J Drug Alcohol Abuse 1986;12:2132-42.
162. Wurmser L. Psychoanalytic considerations of the etiology of compulsive drug abusers. J Am Psychoanal Ass 1974;22:820-43.
163. Nicholson B, Treece C. Object relation and differential treatment respons to methadone maintenance. Journal of Nervous and Mental Disease 1981;169:424-429.
164. Treece C. In: Bellak L, Goldsmith LA, eds. The Broad Scope of Ego Functioning Assessment. New York: Wiley Ed. 1984:268-90.
165. Khantzian EJ, Treece C. DSM III psychiatric diagnosis of narcotic addicts: Recent findings. Arch Gen Psychiatry 1985;42:1065-71.
166. Manna V, Tredanari G, Mescia G. Psicogenesi dellefarmaco-tossicodipendenze: Correlati psicopatologici e prospettive terapeutiche. Salute e Prevenzione 1990;1:63-71.
167. Fromm-Reichmann F. Principi di Psicoterapia. Milano: Feltrinelli Ed. 1962.
168. Minuchin S. Famiglie e Terapia della Famiglia. Roma: Astrolabio Ed. 1974.
169. Selvini Palazzoli M, Boscolo L, Cecchin G, Prata G. Paradosso e Controparadosso. Un Nuovo Modello nella Terapia della Famiglia. Milano: Feltrinelli Ed. 1975.
170. Bion WR. Esperienze nei Gruppi. Roma: Armando Ed. 1971.
171. Borghesi R, Dimauro PE. Comorbilita psichiatrica nell'alcolismo. Boll Farmacodipendenza Alcolismo 1998;1:47-51.
172. Freud S. (1915-1917) Introduzione alla psicoanalisi. Tr. It. In: «Opere». Vol. 8. Torino: Boringhieri Ed. 1980.
173. Freud S. (1914) Introduzione al narcisismo. Tr. It. In: «Opere». Vol. 7 Torino: Boringhieri Ed. 1980.
174. Freud A. (1936). L'lo e i meccanismi di difesa. Tr. It. In: «Opere». Vol. 1. Torino: Boringhieri Ed. 1978.
175. Lipton SD. The advance of Freud's technique as shown in his analysis of the Rat Man. Int J Psycho-Anal 1977;58:255-73.
176. Lipton MA. A letter from Anna Freud. Am J Psychiatry 1983;140:1583-4.
177. Woody GE, Luborsky L, Mclellan AT. Psychotherapy for substances abuse. Psychiatr Clin North America 1986;9:562-73.
178. Wurmser L. Flight from conscience: Experience with the psychoanalytic treatment of compulsive drug abusers, part I: Dynamic sequences, compulsive drug abuses. J Subst Abuse Treat 1987;4:157-68.
179. Thompson Em, Brodie HKH. The psychodynamic of drug therapy. Curr Psychiatr Ther 1981;20:239-51.
180. Krystal H. Integration and Self-Healing: Affect, Trauma, Alexythimia. New York: Hillsdale, Analytic Press 1988.
181. Gallimberti L, Orlandini D, Sartori P, Canton G, Rubini S, Cibin M, et al. Modello Bio-Psico-Sociale di Identificazione dei Sottogruppi di Dipendenti da Oppiacei per la Valutazione dei Trattamento. Atti del «I Congresso C.N.R. Tossico-dipendenze», Firenze 1985.
182. Grassi MC. Profilo farmacologico dei poli-tossicodipendenti. Boll Farmacodipendenze Alcolismo 1988;2:53-8.
183. Orlandini D, Bertinaria A. Indicazionie controindicazioni a trattamenti psicoterapici in alcoldipendenti e loro familiari. In: Ferrara SD, Gallimberti L, eds. La Dipenden za Alcolica. Padova: ARFI RICERCA, Monografia 1, 1988.
184. Zimberg S. La Cura Clinica Dell'alcolismo. Milano: Ferro Ed. 1984.
185. Canton G, Giannini L, Magni G, Bertinaria A, Cibin M, Gallimberti L. Locus of control, life events and treatment outcome in alcohol dependence. Acta Psychiatr Scand 1988;78:18-23.
186. Clerici M, Valsecchi P, Duranti E, Milesi A, Sacchetti E. La comorbidità per uso di sostanze nei disturbi psicotici e nella schizofrenia. Noos 2000;6,2:133-56.
187. Beitman BD, Klerman GL. Integrating Pharmacotherapy and Psychotherapy. Washington D.C.: Am Psychiatr Press 1991.
188. Kaplan HI, Sadock BJ. Pocket Handbook of Psychiatric Drug Treatment. Baltimore, Maryland, USA: Williams & Wilkins 1996.